Novo Nordisk A/S (NYSE:NVO) Shares Sold by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 19.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 3,652 shares of the company’s stock after selling 867 shares during the period. Transcend Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $314,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of NVO. DAVENPORT & Co LLC increased its stake in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after buying an additional 451,641 shares during the period. Wellington Management Group LLP acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at about $42,017,000. DSM Capital Partners LLC increased its stake in Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after buying an additional 286,912 shares during the period. World Investment Advisors LLC increased its stake in Novo Nordisk A/S by 2,655.9% during the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after buying an additional 270,234 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Novo Nordisk A/S by 53.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 729,965 shares of the company’s stock valued at $63,183,000 after buying an additional 254,475 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $88.07 on Monday. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The company has a 50-day moving average of $86.01 and a two-hundred day moving average of $107.99. The stock has a market cap of $395.19 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.